简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Research
HOME
·
02696.HK
HENLIUS(02696.HK): First Patient Dosed in Phase I Clinical Trial of HLX05-N, a Cetuximab Biosimilar, for Metastatic Colorectal Cancer
Tags：
HENLIUS
02696.HK
Clinical Trial
2026-07-08
HENLIUS(02696.HK): Bispecific EGFR/c-MET ADC HLX48 Doses First Patient
Tags：
HENLIUS
02696.HK
Clinical Trial
2026-06-30
Henlius (02696.HK) Serplulimab Approved by EU Commission for First-Line sqNSCLC
Tags：
HENLIUS
02696.HK
Innovative Drugs
2026-06-25
Henlius(02696.HK): HLX3902 Injection (STEAP1xCD3xCD28 Trispecific Antibody) Gets NMPA Approval for Phase I Clinical Trial in Metastatic Castration-Resistant Prostate Cancer
Tags：
HENLIUS
02696.HK
Investigational New Drug application
2026-06-17
Henlius(02696.HK): Hanbeiyou (Pertuzumab Injection) Passes GMP Compliance Inspection, Songjiang Base Eligible for Commercial Production
Tags：
HENLIUS
02696.HK
GMP compliance inspection
2026-06-17
Henlius(02696.HK):Phase 2 Clinical Trial of HLX43 Combined with Serplulimab for Neoadjuvant Treatment of NSCLC Approved in Australia
Tags：
HENLIUS
02696.HK
HLX43
Clinical Trial
2026-06-16
HENLIUS(02696.HK): HLX04-O Meets Primary Endpoint in Global Multicenter Phase 3 Trial for Wet Age-Related Macular Degeneration
Tags：
HENLIUS
02696.HK
Clinical Trial
2026-06-16
HENLIUS(02696.HK): Hanbeiyou (Pertuzumab Injection) Approved by NMPA for HER2-positive Breast Cancer Treatment
Tags：
HENLIUS
02696.HK
New Drug Marketing Application
2026-05-29
Henlius (02696.HK): HLX316 (B7-H3-Targeting Sialidase Fc Fusion Protein) Completes First Patient Dosing in Phase I Trial
Tags：
HENLIUS
02696.HK
first-in-human
2026-05-22
Henlius (02696.HK): HLX48 (EGFR/c-MET Dual-target ADC) Secures Australian Approval for Phase I Clinical Trial
Tags：
HENLIUS
02696.HK
Phase I clinical trial
2026-05-13
Henlius (02696.HK): HLX97 (KAT6A/B Inhibitor) Completes First Patient Dosing in Phase I Clinical Trial for Advanced Solid Tumors
Tags：
HENLIUS
02696.HK
Phase I clinical trial
2026-05-13
Henlius (02696.HK): Self-Developed KAT6A/B Inhibitor HLX97 Approved for Clinical Trial
Tags：
HENLIUS
02696.HK
new drug launch
2026-03-05
HENLIUS(02696.HK): Enters into License Agreement with Eisai, Authorizing Commercialization of Hansoh® for Oncology Indications in Japan
Tags：
HENLIUS
02696.HK
2026-02-05
HENLIUS(02696.HK): Completes H-Share Full Circulation, 182.65 Million Unlisted Shares Converted to H-Shares to List Tomorrow
Tags：
HENLIUS
02696.HK
2026-02-04
Featured News
Research
Daily Report on Hong Kong-Listed LLM Concept Stocks (July 8, 2026)
Finance
China Feihe (06186.HK): Subscribes to RMB 300 Million Financial Products of SPD Bank
Finance
361 Degrees (01361.HK): Change of Independent Non-executive Director, Chan Yee Fong Appointed
ETF
Csop Ftse Hk-Korea Tech+ Index Etf(03431.HK) Rises 0.19% Intraday, Turnover Hits HK$68.9154 Million
ETF
E Fund (Hk) Solactive Asia Semiconductor Select Index Etf(03486.HK) Rises 0.35% Intraday with NAV Per Unit at HK$22.424
ETF
Premia FTSE TWSE Taiwan 50 ETF(03453.HK) Rises 0.74% Intraday with Average Traded Price of HK$169.690
ETF
Ishares Ftse China A50 Etf(02823.HK) Gains 1.01% Intraday at HK$17.00
ETF
E Fund (Hk) Ftse Ai Select Index Etf(03489.HK) Rises 2.09% Intraday, NAV Per Unit Stands at HK$13.264
ETF
ChinaAMC HSI ESG ETF(03403.HK) Rises 2.22% Intraday with Average Traded Price of HK$48.633
ETF
iShares Core MSCI China Index ETF(02801.HK) Rises 3.03% Intraday with AUM of HK$13.168 Billion
Scan QR Code
Download App
